Fig. 2

Patient disposition. ^aA total of 46 patients were enrolled in Part 1; however, 3 patients (1 patient each in the 125, 250 and 2500 mg/m² cohorts) did not receive any study treatment with NUC-3373. ^bSix patients in Part 1 were not evaluable for DLT assessment: 5 patients withdrew in Cycle 1 (3 patients in the 250 mg/m² cohort and 2 patients in the 500 mg/m² cohort) and 1 patient in the 750 mg/m² cohort received less than 3 doses of NUC-3373 (the required 75% of Cycle 1 doses). ^cTwo patients in Part 2 were not evaluable for DLT assessment: 1 patient withdrew in Cycle 1 and 1 patient received less than 2 doses of NUC-3373, both in the 2500 mg/m² cohort.^d One patient discontinued at the discretion of the Investigator due to declining performance status (ECOG 3). Abbreviations: AE = adverse event; DLT = dose-limiting toxicity; ITT = intention-to-treat; PD = progressive disease; Q1W = weekly; Q2W = alternate weekly